MYDAYIS Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mydayis, and when can generic versions of Mydayis launch?
Mydayis is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.
The generic ingredient in MYDAYIS is amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. There are fifty-five drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate profile page.
DrugPatentWatch® Generic Entry Outlook for Mydayis
There have been sixteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MYDAYIS?
- What are the global sales for MYDAYIS?
- What is Average Wholesale Price for MYDAYIS?
Summary for MYDAYIS
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 2 |
| Drug Prices: | Drug price information for MYDAYIS |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for MYDAYIS |
| What excipients (inactive ingredients) are in MYDAYIS? | MYDAYIS excipients list |
| DailyMed Link: | MYDAYIS at DailyMed |
Recent Clinical Trials for MYDAYIS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mayo Clinic | Phase 2 |
| Lindner Center of HOPE | Phase 2 |
| NYU Langone Health | Phase 3 |
Pharmacology for MYDAYIS
| Drug Class | Central Nervous System Stimulant |
| Physiological Effect | Central Nervous System Stimulation |
Paragraph IV (Patent) Challenges for MYDAYIS
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| MYDAYIS | Extended-release Capsules | amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate | 12.5 mg and 25 mg | 022063 | 1 | 2017-08-07 |
| MYDAYIS | Extended-release Capsules | amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate | 37.5 mg and 50 mg | 022063 | 1 | 2017-08-03 |
US Patents and Regulatory Information for MYDAYIS
MYDAYIS is protected by two US patents.
Patents protecting MYDAYIS
Controlled dose drug delivery system
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Controlled dose drug delivery system
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
Expired US Patents for MYDAYIS
International Patents for MYDAYIS
See the table below for patents covering MYDAYIS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Cyprus | 1112335 | ⤷ Sign Up | |
| South Africa | 200502406 | Sustained released delivery of amphetamine salts. | ⤷ Sign Up |
| European Patent Office | 1977736 | ⤷ Sign Up | |
| Norway | 20051986 | ⤷ Sign Up | |
| Mexico | PA05003129 | SUMINISTRO DE LIBERACION PROLONGADA DE SALES DE ANFETAMINA. (SUSTAINED RELEASED DELIVERY OF AMPHETAMINE SALTS.) | ⤷ Sign Up |
| Morocco | 27469 | ADMINISTRATION PAR LIBERATION PROLONGEE DE SELS D'AMPHETAMINE. | ⤷ Sign Up |
| European Patent Office | 1542660 | ADMINISTRATION PAR LIBERATION PROLONGEE DE SELS D'AMPHETAMINE (SUSTAINED RELEASED DELIVERY OF AMPHETAMINE SALTS) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
